{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Null Hypothesis: There is no difference in response rate between 1q21 amplified and 1q21 NOT amplified","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.23","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"}]}],"title":"Non Responder"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"81"}]}],"title":"Responder"},{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"85"}]}],"title":"Total"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"85"}],"units":"Participants"}],"description":"Responders are the number of participants who achieved stringent complete response (sCR)/ complete response (CR), very good partial response (VGPR) or partial response (PR) following PAD induction.","groups":[{"description":"Participants without 1q21 amplification. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG000","title":"1q21 Not Amplified"},{"description":"Participants with 1q21 amplification. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG001","title":"1q21 Amplified"},{"description":"Participants who failed 1q21 test/had missing results for 1q21 test. Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG002","title":"Failed/Missing"},{"description":"Four 21-day cycles of bortezomib 1.3 mg/m2 intravenous (IV) on Days 1, 4, 8 and 11; plus doxorubicin 20 mg/m2 IV on Days 1 and 4; and dexamethasone 20 mg oral on Days 1, 2, 4, 5, 8, 9, 11 and 12.","id":"OG003","title":"Total"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat (ITT) population - All participants who were screened and received at least one dose of PAD","reportingStatus":"POSTED","timeFrame":"3-months following ASCT","title":"Overall Response Rate (ORR) to Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction 3-months Following Autologous Stem Cell Transplant (ASCT).","type":"SECONDARY","unitOfMeasure":"Participants"}